<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vmireaviz</journal-id><journal-title-group><journal-title xml:lang="ru">Вестник медицинского института «РЕАВИЗ». Реабилитация, Врач и Здоровье</journal-title><trans-title-group xml:lang="en"><trans-title>Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2226-762X</issn><issn pub-type="epub">2782-1579</issn><publisher><publisher-name>РЕАВИЗ</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20340/vmi-rvz.2025.3.CLIN.8</article-id><article-id custom-type="elpub" pub-id-type="custom">vmireaviz-1334</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Клиническая медицина</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Clinical medicine</subject></subj-group></article-categories><title-group><article-title>Поперечное исследование распределения сердечно-сосудистых заболеваний и факторов риска у пациентов с раком предстательной железы с потенциальными показаниями для эндокринной терапии</article-title><trans-title-group xml:lang="en"><trans-title>Cross-sectional study of the distribution of cardiovascular diseases and risk factors in patients with prostate cancer with potential indications for endocrine therapy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Синьи</surname><given-names>Я.</given-names></name><name name-style="western" xml:lang="en"><surname>Xinyi</surname><given-names>Ya.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ян Синьи - Университетская клиническая больница № 1 Вклад автора: концепция и дизайн исследования, подготовка текста работы, работа с источниками, анализ и обобщение полученных данных.</p><p>ул. Трубецкая, д. 8/2, г. Москва, 119991</p></bio><bio xml:lang="en"><p>Yang Xinyi - University Clinical Hospital No. 1 Author's contribution: concept and design of the study, preparation of the text of the work, work with sources, analysis and generalization of the obtained data.</p><p>8/2, Trubetskaya st., Moscow, 119991</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Агакина</surname><given-names>Ю. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Agakina</surname><given-names>Yu. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Агакина Ю.С. - Университетская клиническая больница № 1 Вклад автора: концепция и дизайн исследования, подготовка текста работы, работа с источниками, анализ и обобщение полученных данных.</p><p>ул. Трубецкая, д. 8/2, г. Москва, 119991</p></bio><bio xml:lang="en"><p>Yuliya S. Agakina - University Clinical Hospital No. 1 Author's contribution: concept and design of the study, preparation of the text of the work, work with sources, analysis and generalization of the obtained data.</p><p>8/2, Trubetskaya st., Moscow, 119991</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Минцзэ</surname><given-names>Х.</given-names></name><name name-style="western" xml:lang="en"><surname>Mingze</surname><given-names>H.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Хэ Минцзэ - Институт урологии и репродуктивного здоровья человека Вклад автора: концепция и дизайн исследования, подготовка текста работы, работа с источниками, анализ и обобщение полученных данных.</p><p>ул. Трубецкая, д. 8/2, г. Москва, 119991</p></bio><bio xml:lang="en"><p>He Mingze - Institute of Urology and Human Reproductive Health Author's contribution: concept and design of the study, preparation of the text of the work, work with sources, analysis and generalization of the obtained data.</p><p>8/2, Trubetskaya st., Moscow, 119991</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Цзитун</surname><given-names>Ц.</given-names></name><name name-style="western" xml:lang="en"><surname>Zitong</surname><given-names>Z.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Цзен Цзитун - Университетская клиническая больница № 1 Вклад автора: концепция и дизайн исследования, подготовка текста работы, работа с источниками, анализ и обобщение полученных данных.</p><p>ул. Трубецкая, д. 8/2, г. Москва, 119991</p></bio><bio xml:lang="en"><p>Zeng Zitong - University Clinical Hospital No. 1 Author's contribution: concept and design of the study, preparation of the text of the work, work with sources, analysis and generalization of the obtained data.</p><p>8/2, Trubetskaya st., Moscow, 119991</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Юйяо</surname><given-names>Х.</given-names></name><name name-style="western" xml:lang="en"><surname>Yuyao</surname><given-names>H.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Хань Юйяо - Университетская клиническая больница № 1 Вклад автора: концепция и дизайн исследования, подготовка текста работы, работа с источниками, анализ и обобщение полученных данных.</p><p>ул. Трубецкая, д. 8/2, г. Москва, 119991</p></bio><bio xml:lang="en"><p>Han Yuyao - University Clinical Hospital No. 1  Author's contribution: concept and design of the study, preparation of the text of the work, work with sources, analysis and generalization of the obtained data.</p><p>8/2, Trubetskaya st., Moscow, 119991</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Щицзюнь</surname><given-names>С.</given-names></name><name name-style="western" xml:lang="en"><surname>Shijun</surname><given-names>X.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сюй Щицзюнь - Университетская клиническая больница № 1 Вклад автора: концепция и дизайн исследования, подготовка текста работы, работа с источниками, анализ и обобщение полученных данных.</p><p>ул. Трубецкая, д. 8/2, г. Москва, 119991</p></bio><bio xml:lang="en"><p>Xu Shijun - University Clinical Hospital No. 1 Author's contribution: concept and design of the study, preparation of the text of the work, work with sources, analysis and generalization of the obtained data.</p><p>8/2, Trubetskaya st., Moscow, 119991</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Первый московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)<country>Россия</country></aff><aff xml:lang="en">Sechenov First Moscow State Medical University (Sechenov University)<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>01</day><month>08</month><year>2025</year></pub-date><volume>15</volume><issue>3</issue><fpage>138</fpage><lpage>144</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Синьи Я., Агакина Ю.С., Минцзэ Х., Цзитун Ц., Юйяо Х., Щицзюнь С., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Синьи Я., Агакина Ю.С., Минцзэ Х., Цзитун Ц., Юйяо Х., Щицзюнь С.</copyright-holder><copyright-holder xml:lang="en">Xinyi Y., Agakina Y.S., Mingze H., Zitong Z., Yuyao H., Shijun X.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://vestnik.reaviz.ru/jour/article/view/1334">https://vestnik.reaviz.ru/jour/article/view/1334</self-uri><abstract><p>Цель: исследование направлено на оценку распространенности сердечно-сосудистых заболеваний (ССЗ) и факторов риска у пациентов с раком предстательной железы (РПЖ) до начала эндокринной терапии (ЭТ), что необходимо для снижения потенциальных побочных эффектов лечения и улучшения прогноза. Объект и методы. В исследование включены 59 пациентов с впервые диагностированным РПЖ, не получавших ранее ЭТ, наблюдавшихся в Первой университетской клинической больнице Сеченовского университета в 2018–2022 гг. Изучены клинико-лабораторные параметры, распространенность ССЗ и метаболических нарушений, проведена стратификация сердечно-сосудистого риска по шкале ASCVD. Результаты. 83% пациентов имели как минимум одно ССЗ; наиболее частой коморбидностью оказалась гипертония (79%), контроль давления был неудовлетворительным у пациентов с высоким и очень высоким риском. Дислипидемия выявлена у 61%, наиболее частыми отклонениями были сниженный уровень ЛПВП и повышенные триглицериды. Только 19% пациентов использовали липидоснижающие препараты. Стратификация риска по ASCVD показала недостаточное достижение целевых уровней ЛПНП, особенно у пациентов с высоким риском. Выводы. Высокая распространенность ССЗ у пациентов с РПЖ до начала ЭТ подчеркивает необходимость раннего выявления и коррекции факторов риска. Комплексный междисциплинарный подход должен стать неотъемлемой частью ведения таких пациентов.</p></abstract><trans-abstract xml:lang="en"><p>Objective: this study aims to evaluate the prevalence of cardiovascular diseases (CVD) and associated risk factors in patients with prostate cancer (PCa) prior to initiation of endocrine therapy (ET), as a basis for reducing treatment-related complications and improving patient outcomes. Materials and Methods. A total of 59 newly diagnosed, treatment-naïve PCa patients with potential indications for ET were enrolled at Sechenov University Clinical Hospital No. 1 between May 2018 and July 2022. Clinical and laboratory data were collected, and cardiovascular risk was assessed using ASCVD stratification. Results. 83% of patients had at least one CVD; hypertension (79%) was the most prevalent condition. Blood pressure control was insufficient among patients at high cardiovascular risk. Dyslipidemia was present in 61%, mainly characterized by low HDL-C and elevated triglycerides. Only 19% of patients were on lipid-lowering therapy, and LDL-C target attainment was especially poor among high-risk patients. Conclusion. The high prevalence of CVD and poor control of modifiable risk factors prior to ET initiation emphasize the need for early cardiovascular risk assessment and management. A multidisciplinary care model is essential to optimize treatment outcomes in PCa patients.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>сердечно-сосудистые заболевания [C14.280]</kwd><kwd>эндокринная терапия [E02.779.474]</kwd><kwd>рак предстательной железы [C04.588.945.440.770]</kwd><kwd>гипертония [C14.907.489]</kwd><kwd>дислипидемия [C18.452.394.750]</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Cardiovascular Diseases [C14.280]</kwd><kwd>Endocrine Therapy [E02.779.474]</kwd><kwd>Prostatic Neoplasms [C04.588.945.440.770]</kwd><kwd>Hypertension [C14.907.489]</kwd><kwd>Dyslipidemias [C18.452.394.750]</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.</mixed-citation><mixed-citation xml:lang="en">Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Culp MB, Soerjomataram I, Efstathiou JA, et al. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77(1):38-52.</mixed-citation><mixed-citation xml:lang="en">Culp MB, Soerjomataram I, Efstathiou JA, et al. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77(1):38-52.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Leong DP, Fradet V, Shayegan B, et al. Cardiovascular risk in men with prostate cancer: Insights from the RADICAL PC study. J Urol. 2020;203(6):1109-1116.</mixed-citation><mixed-citation xml:lang="en">Leong DP, Fradet V, Shayegan B, et al. Cardiovascular risk in men with prostate cancer: Insights from the RADICAL PC study. J Urol. 2020;203(6):1109-1116.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Sturgeon KM, Deng L, Bluethmann SM, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40(48):3889-3897.</mixed-citation><mixed-citation xml:lang="en">Sturgeon KM, Deng L, Bluethmann SM, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40(48):3889-3897.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ng HS, Koczwara B, Roder D, et al. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study. Prostate Cancer Prostatic Dis. 2018;21(3):403-410.</mixed-citation><mixed-citation xml:lang="en">Ng HS, Koczwara B, Roder D, et al. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study. Prostate Cancer Prostatic Dis. 2018;21(3):403-410.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Veccia A, Maines F, Kinspergher S, et al. Cardiovascular toxicities of systemic treatments of prostate cancer. Nat Rev Urol. 2017;14(4):230-243.</mixed-citation><mixed-citation xml:lang="en">Veccia A, Maines F, Kinspergher S, et al. Cardiovascular toxicities of systemic treatments of prostate cancer. Nat Rev Urol. 2017;14(4):230-243.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Gandaglia G, Sun M, Popa I, et al. Cardiovascular mortality in patients with metastatic prostate cancer exposed to androgen deprivation therapy: a population-based study. Clin Genitourin Cancer. 2015;13(3):e123-e130.</mixed-citation><mixed-citation xml:lang="en">Gandaglia G, Sun M, Popa I, et al. Cardiovascular mortality in patients with metastatic prostate cancer exposed to androgen deprivation therapy: a population-based study. Clin Genitourin Cancer. 2015;13(3):e123-e130.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Keating NL, O'Malley AJ, Freedland SJ, et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102(1):39-46.</mixed-citation><mixed-citation xml:lang="en">Keating NL, O'Malley AJ, Freedland SJ, et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102(1):39-46.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Bosco C, Bosnyak Z, Malmberg A, et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2015;68(3):386-396.</mixed-citation><mixed-citation xml:lang="en">Bosco C, Bosnyak Z, Malmberg A, et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2015;68(3):386-396.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Van Hemelrijck M, Garmo H, Holmberg L, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol. 2010;28(21):3448-3456.</mixed-citation><mixed-citation xml:lang="en">Van Hemelrijck M, Garmo H, Holmberg L, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol. 2010;28(21):3448-3456.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kunath F, Jensen K, Pinart M, et al. Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer. Cochrane Database Syst Rev. 2019;6(6):CD003506.</mixed-citation><mixed-citation xml:lang="en">Kunath F, Jensen K, Pinart M, et al. Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer. Cochrane Database Syst Rev. 2019;6(6):CD003506.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Diaconu R, Donoiu I, Mirea O, Bălşeanu TA. Testosterone, cardiomyopathies, and heart failure: a narrative review. Asian J Androl. 2021;23(4):348-356.</mixed-citation><mixed-citation xml:lang="en">Diaconu R, Donoiu I, Mirea O, Bălşeanu TA. Testosterone, cardiomyopathies, and heart failure: a narrative review. Asian J Androl. 2021;23(4):348-356.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kelly WK, Gomella LG. Androgen deprivation therapy and competing risks. JAMA. 2011;306(21):2382-2383.</mixed-citation><mixed-citation xml:lang="en">Kelly WK, Gomella LG. Androgen deprivation therapy and competing risks. JAMA. 2011;306(21):2382-2383.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Levine GN, D'Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010;60(3):194-201.</mixed-citation><mixed-citation xml:lang="en">Levine GN, D'Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010;60(3):194-201.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Kolinsky M, de Bono JS. The ongoing challenges of targeting the androgen receptor. Eur Urol. 2016;69(5):841-843.</mixed-citation><mixed-citation xml:lang="en">Kolinsky M, de Bono JS. The ongoing challenges of targeting the androgen receptor. Eur Urol. 2016;69(5):841-843.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Jespersen CG, Nørgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol. 2014;65(4):704-709.</mixed-citation><mixed-citation xml:lang="en">Jespersen CG, Nørgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol. 2014;65(4):704-709.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS. Secondary hormonal therapy for advanced prostate cancer. J Urol. 2006;175(1):27-34.</mixed-citation><mixed-citation xml:lang="en">Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS. Secondary hormonal therapy for advanced prostate cancer. J Urol. 2006;175(1):27-34.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Hedlund PO, Johansson R, Damber JE, et al. Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial. Scand J Urol Nephrol. 2011;45(5):346-353.</mixed-citation><mixed-citation xml:lang="en">Hedlund PO, Johansson R, Damber JE, et al. Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial. Scand J Urol Nephrol. 2011;45(5):346-353.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Smith MR, Saad F, Egerdie B, et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol. 2012;30(26):3271-3276.</mixed-citation><mixed-citation xml:lang="en">Smith MR, Saad F, Egerdie B, et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol. 2012;30(26):3271-3276.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448-4456.</mixed-citation><mixed-citation xml:lang="en">Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448-4456.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Rezaei MM, Rezaei MM, Ghoreifi A, et al. Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy. Can Urol Assoc J. 2016;10(9-10):E300-E305.</mixed-citation><mixed-citation xml:lang="en">Rezaei MM, Rezaei MM, Ghoreifi A, et al. Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy. Can Urol Assoc J. 2016;10(9-10):E300-E305.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Gupta D, Lee Chuy K, Yang JC, et al. Cardiovascular and metabolic effects of androgen-deprivation therapy for prostate cancer. J Oncol Pract. 2018;14(10):580-587.</mixed-citation><mixed-citation xml:lang="en">Gupta D, Lee Chuy K, Yang JC, et al. Cardiovascular and metabolic effects of androgen-deprivation therapy for prostate cancer. J Oncol Pract. 2018;14(10):580-587.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Gagliano-Jucá T, Travison TG, Kantoff PW, et al. Androgen deprivation therapy is associated with prolongation of QTc interval in men with prostate cancer. J Endocr Soc. 2018;2(5):485-496.</mixed-citation><mixed-citation xml:lang="en">Gagliano-Jucá T, Travison TG, Kantoff PW, et al. Androgen deprivation therapy is associated with prolongation of QTc interval in men with prostate cancer. J Endocr Soc. 2018;2(5):485-496.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Smith MR, Klotz L, Persson BE, Olesen TK, et al. Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, openlabel, parallel-group phase III trial in patients with prostate cancer. J Urol. 2010;184(6):2313-2319.</mixed-citation><mixed-citation xml:lang="en">Smith MR, Klotz L, Persson BE, Olesen TK, et al. Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, openlabel, parallel-group phase III trial in patients with prostate cancer. J Urol. 2010;184(6):2313-2319.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
